Commentary
Hitting HIV where it hides
-
Correspondence: Andrew I Dayton Andrew.dayton@fda.hhs.gov
Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases, OBRR/CBER/FDA, HFM 315, 1401 Rockville Pike, Rockville, MD 20852-1448, USA
Retrovirology 2008, 5:15 doi:10.1186/1742-4690-5-15
Published: 1 February 2008Abstract
The recent finding that inhibitors of PI3/Akt can sensitize HIV infected macrophages to oxidative stress-induced cell death suggest a potential new therapeutic approach to targeting HIV reservoirs.